Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Philipp B. Staber; Marco Herling; Mar Bellido; Eric D. Jacobsen; Matthew S. Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E. Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden

doi:10.1182/blood.2019000402

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch-Klupp, Claudia Haferlach, Stefan Kubicek, Marius E. Mayerhoefer, Georg Hopfinger, Ulrich Jaeger, Claire Dearden

Leukemia

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

Original language	English (US)
Pages (from-to)	1132-1143
Number of pages	12
Journal	Blood
Volume	134
Issue number	14
DOIs	https://doi.org/10.1182/blood.2019000402
State	Published - Oct 3 2019

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019000402

Cite this

Staber, P. B., Herling, M., Bellido, M., Jacobsen, E. D., Davids, M. S., Kadia, T. M., Shustov, A., Tournilhac, O., Bachy, E., Zaja, F., Porkka, K., Hoermann, G., Simonitsch-Klupp, I., Haferlach, C., Kubicek, S., Mayerhoefer, M. E., Hopfinger, G., Jaeger, U., & Dearden, C. (2019). Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 134(14), 1132-1143. https://doi.org/10.1182/blood.2019000402

Staber, PB, Herling, M, Bellido, M, Jacobsen, ED, Davids, MS, Kadia, TM, Shustov, A, Tournilhac, O, Bachy, E, Zaja, F, Porkka, K, Hoermann, G, Simonitsch-Klupp, I, Haferlach, C, Kubicek, S, Mayerhoefer, ME, Hopfinger, G, Jaeger, U & Dearden, C 2019, 'Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia', Blood, vol. 134, no. 14, pp. 1132-1143. https://doi.org/10.1182/blood.2019000402

@article{8fb5483ab5b346ed8d3459dba5aed03f,

title = "Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia",

abstract = "T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.",

author = "Staber, {Philipp B.} and Marco Herling and Mar Bellido and Jacobsen, {Eric D.} and Davids, {Matthew S.} and Kadia, {Tapan Mahendra} and Andrei Shustov and Olivier Tournilhac and Emmanuel Bachy and Francesco Zaja and Kimmo Porkka and Gregor Hoermann and Ingrid Simonitsch-Klupp and Claudia Haferlach and Stefan Kubicek and Mayerhoefer, {Marius E.} and Georg Hopfinger and Ulrich Jaeger and Claire Dearden",

year = "2019",

month = oct,

day = "3",

doi = "10.1182/blood.2019000402",

language = "English (US)",

volume = "134",

pages = "1132--1143",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "14",

}

TY - JOUR

T1 - Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

AU - Staber, Philipp B.

AU - Herling, Marco

AU - Bellido, Mar

AU - Jacobsen, Eric D.

AU - Davids, Matthew S.

AU - Kadia, Tapan Mahendra

AU - Shustov, Andrei

AU - Tournilhac, Olivier

AU - Bachy, Emmanuel

AU - Zaja, Francesco

AU - Porkka, Kimmo

AU - Hoermann, Gregor

AU - Simonitsch-Klupp, Ingrid

AU - Haferlach, Claudia

AU - Kubicek, Stefan

AU - Mayerhoefer, Marius E.

AU - Hopfinger, Georg

AU - Jaeger, Ulrich

AU - Dearden, Claire

PY - 2019/10/3

Y1 - 2019/10/3

N2 - T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

AB - T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

UR - http://www.scopus.com/inward/record.url?scp=85072944454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072944454&partnerID=8YFLogxK

U2 - 10.1182/blood.2019000402

DO - 10.1182/blood.2019000402

M3 - Article

C2 - 31292114

AN - SCOPUS:85072944454

SN - 0006-4971

VL - 134

SP - 1132

EP - 1143

JO - Blood

JF - Blood

IS - 14

ER -

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this